Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
- Conditions
- Heroin DependenceOpioid-Related Disorders
- Interventions
- Drug: Placebo DrugDrug: Test Drug
- Registration Number
- NCT00000331
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.
- Detailed Description
not available at this time
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age, and have no prior history of drug or alcohol abuse or dependence. Subjects must have had some minimal experience with opioids (e.g. at least two prior exposures)
Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Placebo Pill Placebo Drug Placebo drug Test Drug Test Drug Test drug to prevent heroine withdrawal
- Primary Outcome Measures
Name Time Method Observed withdrawal rating Drug effect characteristics Pupil diameter
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States